Stivarga® (regorafinib) – New orphan indication
April 27, 2017 – The FDA announced the approval of Bayer’s Stivarga (regorafinib), for the treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with Nexavar® (sorafenib).
Download PDF
